文献速递临床试验与 GCP

经导管缘对缘修复治疗重度孤立性三尖瓣反流:Tri.Fr随机临床试验

Transcatheter Edge-to-Edge Repair for Severe Isolated Tricuspid Regurgitation: The Tri.Fr Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01

Tri.Fr试验在法国和比利时24个中心前瞻性随机纳入300例重度症状性三尖瓣反流成人患者,1:1分配至三尖瓣经导管缘对缘修复(T-TEER)联合指南导向优化药物治疗(OMT)组(152例)或单纯OMT组(148例)。1年时T-TEER+OMT组74.1%患者复合评分改善,高于单纯OMT组的40.6%;T-TEER降低三尖瓣反流严重程度并改善以患者报告结局驱动的复合评分。

要点

  • 1年时T-TEER+OMT组109例(74.1%)复合评分改善,单纯OMT组58例(40.6%)。
  • 大量或洪流性三尖瓣反流T-TEER+OMT组6.8%,单纯OMT组53.5%(P < .001)。
  • 1年KCCQ总结评分均值T-TEER+OMT组69.9(SD 25.5),单纯OMT组55.4(SD 28.8)(P < .001)。

核心结论

  • 在重度症状性三尖瓣反流患者中,T-TEER降低三尖瓣反流严重程度,并改善以患者报告结局改善驱动的复合评分。

研究设计与样本

  • 研究者发起的、前瞻性、1:1随机试验,在法国和比利时的24个中心开展(2021年3月至2023年3月;末次随访2024年4月)。
  • 纳入重度症状性三尖瓣反流成人患者300例,平均年龄78岁(SD 6),女性63.7%;152例分配至T-TEER+OMT组,148例分配至单纯OMT组。
  • 主要结局为1年复合临床终点,包括纽约心脏病协会心功能分级变化、患者整体评估变化或主要心血管事件发生。

主要发现

  • 1年时T-TEER+OMT组109例(74.1%)复合评分改善,单纯OMT组58例(40.6%)。
  • 大量或洪流性三尖瓣反流T-TEER+OMT组6.8%,单纯OMT组53.5%(P < .001)。
  • 1年KCCQ总结评分均值T-TEER+OMT组69.9(SD 25.5),单纯OMT组55.4(SD 28.8)(P < .001)。
  • 复合次要结局的胜率为2.06(95%CI 1.38-3.08)(P < .001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Correction of tricuspid regurgitation using tricuspid transcatheter edge-to-edge repair (T-TEER) in addition to guideline-directed optimized medical therapy (OMT) may improve clinical outcomes. OBJECTIVE: To evaluate the efficacy of T-TEER + OMT vs OMT alone in patients with severe, symptomatic tricuspid regurgitation. DESIGN, SETTING, AND PARTICIPANTS: Investigator-initiated, prospective, randomized (1:1) trial evaluating T-TEER + OMT vs OMT alone in adult patients with severe, symptomatic tricuspid regurgitation. The trial was conducted at 24 centers in France and Belgium (March 2021 to March 2023; latest follow-up in April 2024). INTERVENTION: Patients were randomized to T-TEER + OMT or OMT alone. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite clinical end point at 1 year comprising change in New York Heart Association class, change in patient global assessment, or occurrence of major cardiovascular events. Tricuspid regurgitation severity was the first of 6 secondary outcomes analyzed in a hierarchical closed-testing procedure, including Kansas City Cardiomyopathy Questionnaire (KCCQ) score, patient global assessment, and a composite outcome of all-cause death, tricuspid valve surgery, KCCQ score improvement, or time to hospitalization for heart failure. RESULTS: Of 300 enrolled patients (mean age, 78 [SD, 6] years, 63.7% women), 152 were allocated to T-TEER + OMT and 148 to OMT alone. At 1 year, 109 patients (74.1%) in the T-TEER + OMT group had an improved composite score compared with 58 patients (40.6%) in the OMT-alone group. Massive or torrential tricuspid regurgitation was found in 6.8% of patients in the T-TEER + OMT group and in 53.5% of those in the OMT-alone group (P < .001). Mean overall KCCQ summary score at 1 year was 69.9 (SD, 25.5) for the T-TEER + OMT group and 55.4 (SD, 28.8) for the OMT-alone group (P < .001). The win ratio for the composite secondary outcome was 2.06 (95% CI, 1.38-3.08) (P < .001). CONCLUSIONS AND RELEVANCE: T-TEER reduces tricuspid regurgitation severity and improves a composite score driven by improved patient-reported outcome measures in patients with severe, symptomatic tricuspid regurgitation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04646811.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Donal E, Dreyfus J, Leurent G, et al. Transcatheter Edge-to-Edge Repair for Severe Isolated Tricuspid Regurgitation: The Tri.Fr Randomized Clinical Trial. JAMA. 2025. PMID: 39602173. doi:10.1001/jama.2024.21189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。